Human Genome, Glaxo To Face FDA Panel For Lupus Drug
November 11 2010 - 4:36PM
Dow Jones News
Human Genome Sciences Inc. (HGSI) and GlaxoSmithKline Plc (GSK,
GSK.LN) are seeking to take a significant step next week in getting
regulatory approval for the first new treatment to fight the
autoimmune disease lupus in more than 50 years.
A U.S. Food and Drug Administration panel will decide Tuesday
whether the companies' drug Benlysta should be approved by the
agency in early December.
The drug showed surprise success in two late-stage studies last
year--transforming Human Genome's stock market value--as analysts
project annual sales eventually exceeding $1 billion a year. The
drug is widely expected to get FDA approval because of its strong
data and the lack of alternatives for patients.
"It is a beacon of hope. There hasn't been, in the history of
the disease, a drug aimed specifically at lupus," said Sandra
Raymond, president of the Lupus Foundation of America.
Lupus, which primarily strikes women of childbearing age, occurs
when the body attacks itself, causing inflammation and tissue
damage virtually anywhere in the body. The Lupus Foundation of
America estimates that 1.5 million Americans have the disease,
although Human Genome initially plans to target about 200,000
patients with moderate or severe forms of the disease.
Because the disease could cause many symptoms in different
patients, physicians traditionally use different treatments,
including anti-inflammatory drugs, steroids, anti-malarials and
immunosuppressants.
Leerink Swann projects that world-wide sales of the drug will
exceed $5 billion in 2020. The drug's success has produced
consistent speculation that Glaxo, or another large drug maker,
would acquire the company.
Shares of Human Genome closed at $26.48 Thursday; they had
traded below $1 just months prior to the initial Phase III data on
the drug last year. The stock ended up 8.8% ahead of Friday's
expected release of briefing documents related to the panel's
deliberations.
RBC Capital Markets recently projected that Human Genome's stock
would rise above $30 on a positive recommendation from the panel,
but could drop 50% to 60% if it gets a negative vote. The firm
gives only a 5% to 10% chance of a rejection.
In late-stage trials, Benlysta patients showed a greater
response to the drug, compared with placebo, in a combination of
several disease-activity measures, including flares and symptom
severity. Human Genome worked with the FDA on the studies' complex
design that attempted to isolate the patient group that responded
in a failed mid-stage trial.
The panel next week is expected to discuss the drug's
complicated late-stage trials, along with the drug's safety
profile, including the potential for an increased risk of infection
and slight increase in some types of cancer. Most believe the
benefits of the drug will outweigh those concerns and result in
strong warnings on the drug's label, as has occurred on most
rheumatoid arthritis treatments.
Benlysta is an antibody that blocks the activity of a protein
required for the development of certain B cells, part of the immune
system, that produce antibodies thought to play a key role in lupus
and some other autoimmune diseases.
The nature of the disease makes it difficult to treat and a
challenge to design clinical trials because almost every patient
has different symptoms and, accordingly, gets different treatments.
Numerous efforts over the years to develop new therapies have led
to a string of major disappointments.
Current companies pursuing lupus research include UCB SA
(UCB.BT) and Immunomedics Inc. (IMMU), Cephalon Inc. (CEPH) and
ImmuPharma Plc (IMM.LN), and Astrazeneca Plc. (AZN, AZN.LN).
While some companies have drugs in development, there is hope
that the clinical success of Benlysta and its potential approval
will attract even more research in lupus by proving it is a viable
area for major drug companies.
"It shows companies that it is possible to show a therapeutic
benefit in lupus," said Chaim Putterman, chief of rheumatology at
Albert Einstein College of Medicine and Montefiore Medical Center.
He said he expects Benlysta to get widespread use and is hopeful
that other medications in development will show similar
benefits.
"It encourages other companies to begin to look at lupus as a
potential disease of interest," he said.
-By Thomas Gryta, Dow Jones Newswires; 212-416-2169;
thomas.gryta@dowjones.com
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024